HomeProductsBioactive CompoundsNeuronal SignalingAmyloid-??Semagacestat
Chemical structure of CAS 425386-60-3

Semagacestat

In Stock•Starting at $100 for 25 mg•Purity ≥ 98%
CAS No.425386-60-3
MDL No.MFCD09970409
MFC19H27N3O4
MW361.40
InChI KeyPKXWXXPNHIWQHW-RCBQFDQVSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
25 mg98%$100In Stock
50 mg98%$170In Stock
100 mg98%$286In Stock
250 mg98%$587In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

(2S)-2-Hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide is a peptide.

CAS No.425386-60-3
Product NameSemagacestat

Biological Targets

APH1A·PSENEN·APH1B·PSEN1·NCSTN·

Associated Conditions

Alzheimer disease
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.

CNS neuroscience & therapeutics • Vol. 16, Issue 5 • 2010
PMID: 20560993PMC: PMC6493789DOI: 10.1111/j.1755-5949.2010.00164.x

A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease.

Alzheimer's research & therapy • Vol. 2, Issue 2 • 2010
PMID: 20350302PMC: PMC2876785DOI: 10.1186/alzrt30

Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 38, Issue 4 • 2010
PMID: 20075192DOI: 10.1124/dmd.109.030841

Recent developments in Alzheimer's disease therapeutics.

BMC medicine • Vol. 7 • 2009
PMID: 19228370PMC: PMC2649159DOI: 10.1186/1741-7015-7-7

Documentation

Similar Products